BiomeBank's mission is to treat and prevent disease by replenishing gut microbial ecology. The company has developed BiomeBoost which is provisionally approved for supply as a class 2 biologic under TGO 105 for the treatment of recurrent or refractory Clostridioides difficile infection. BiomeBank is developing a Pipeline of microbial therapies in multiple indications.
Experienced microbiome drug developer who has successfully led multiple microbiome drug development and biomarker programs, from discovery through to phased clinical trials, in Boston and Cambridge UK.
World leading microbiome scientist who has pioneered key research in the field of metagenomics and anaerobic culturing. Sam holds academic positions at the Sanger and Hudson Medical Research Institute. See publications.